{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T10:34:37Z","timestamp":1786617277282,"version":"build-2736575974"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hum Hypertens"],"DOI":"10.1038\/s41371-026-01189-8","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T08:47:02Z","timestamp":1786610822000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Triple drug antihypertensive single-pill combinations included as WHO essential medicines: an overview of efficacy, safety, and cost"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2211-145X","authenticated-orcid":false,"given":"Gautam","family":"Satheesh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5870-7936","authenticated-orcid":false,"given":"Abdul","family":"Salam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupasvi","family":"Dhurjati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2225-383X","authenticated-orcid":false,"given":"Paul K.","family":"Whelton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Perel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrianna","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2084-1988","authenticated-orcid":false,"given":"Dike","family":"Ojji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Asita","family":"de Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elijah","family":"Ogola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ntobeko A. B.","family":"Ntusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Gaziano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3172-834X","authenticated-orcid":false,"given":"Dorairaj","family":"Prabhakaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7498-4634","authenticated-orcid":false,"given":"Sohel Reza","family":"Choudhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana G.","family":"Munera Echeverri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7412-2519","authenticated-orcid":false,"given":"Mark D.","family":"Huffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9217-4937","authenticated-orcid":false,"given":"Aletta E.","family":"Schutte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3554-0085","authenticated-orcid":false,"given":"Andrew E.","family":"Moran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1282-1896","authenticated-orcid":false,"given":"Anthony","family":"Rodgers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"1189_CR1","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(21)01330-1","volume":"398","author":"NCD Risk Factors Collaboration","year":"2021","unstructured":"NCD Risk Factors Collaboration. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990\u20132019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398:957\u201380.","journal-title":"Lancet"},{"key":"1189_CR2","volume-title":"Guideline for the pharmacological treatment of hypertension in adults","author":"World Health Organization","year":"2021","unstructured":"World Health Organization. Guideline for the pharmacological treatment of hypertension in adults. Geneva: World Health Organization; 2021. Report No.: Licence: CC BY-NC-SA 3.0 IGO"},{"key":"1189_CR3","doi-asserted-by":"publisher","first-page":"e212","DOI":"10.1161\/HYP.0000000000000249","volume":"82","author":"DW Jones","year":"2025","unstructured":"Writing Committee Members*, Jones DW, Ferdinand KC, Taler SJ, Johnson HM, Liaison JC, et al. 2025 AHA\/ACC\/AANP\/AAPA\/ABC\/ACCP\/ACPM\/AGS\/AMA\/ASPC\/NMA\/PCNA\/SGIM Guideline for the prevention, detection, evaluation and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines. Hypertension. 2025;82:e212\u2013e316.","journal-title":"Hypertension"},{"key":"1189_CR4","doi-asserted-by":"publisher","first-page":"ehae178","DOI":"10.1093\/eurheartj\/ehae178","volume":"45","author":"JW McEvoy","year":"2024","unstructured":"McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. 2024 ESC guidelines for the management of elevated blood pressure and hypertension: developed by the task force on the management of elevated blood pressure and hypertension of the european society of cardiology (ESC) and endorsed by the European Society of Endocrinology (ESE) and the European Stroke Organisation (ESO). Eur Heart J. 2024;45:ehae178.","journal-title":"Eur Heart J"},{"key":"1189_CR5","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"G Mancia","year":"2023","unstructured":"Mancia G, Kreutz R, Brunstr\u00f6m M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European Society of Hypertension: endorsed by the international society of hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41:1874\u20132071.","journal-title":"J Hypertens"},{"key":"1189_CR6","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/S0140-6736(25)00991-2","volume":"406","author":"N Wang","year":"2025","unstructured":"Wang N, Salam A, Pant R, Kumar A, Dhurjati R, Haghdoost F, et al. Blood pressure-lowering efficacy of antihypertensive drugs and their combinations: a systematic review and meta-analysis of randomised, double-blind, placebo-controlled trials. Lancet. 2025;406:915\u201325.","journal-title":"Lancet"},{"key":"1189_CR7","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1097\/HJH.0000000000000440","volume":"33","author":"S Laurent","year":"2015","unstructured":"Laurent S, Parati G, Chazova I, Sirenko Y, Erglis A, Laucevicius A, et al. Randomized evaluation of a novel, fixed-dose combination of perindopril 3.5\u200amg\/amlodipine 2.5\u200amg as a first-step treatment in hypertension. J Hypertens. 2015;33:653\u201361.","journal-title":"J Hypertens"},{"key":"1189_CR8","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1161\/CIRCRESAHA.118.313294","volume":"124","author":"G Mancia","year":"2019","unstructured":"Mancia G, Rea F, Corrao G, Grassi G. Two-drug combinations as first-step antihypertensive treatment. Circ Res. 2019;124:1113\u201323.","journal-title":"Circ Res"},{"key":"1189_CR9","unstructured":"Satheesh G, Dhurjati R, Salam A, Moran AE, Murphy A, Perel P, et al. Application for the addition of triple drug fixed-dose antihypertensive medicine combinations on the Model List of Essential Medicines for treatment of essential hypertension in adults. Geneva: WHO; 2025 [cited 2025 Sep 22]. https:\/\/cdn.who.int\/media\/docs\/default-source\/2025-eml-expert-committee\/addition-of-new-medicines\/a.29_triple-fdc-antihypertensive.pdf?sfvrsn=9f9eef50_6."},{"key":"1189_CR10","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1161\/HYPERTENSIONAHA.120.15781","volume":"77","author":"G Parati","year":"2021","unstructured":"Parati G, Kjeldsen S, Coca A, Cushman WC, Wang J. Adherence to single-pill versus free-equivalent combination therapy in hypertension: a systematic review and meta-analysis. Hypertension. 2021;77:692\u2013705.","journal-title":"Hypertension"},{"key":"1189_CR11","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s40292-023-00563-8","volume":"30","author":"M Burnier","year":"2023","unstructured":"Burnier M, Redon J, Volpe M. Single-pill combination with three antihypertensive agents to improve blood pressure control in hypertension: focus on olmesartan-based combinations. High Blood Press Cardiovascular Prev. 2023;30:109\u201321.","journal-title":"High Blood Press Cardiovascular Prev"},{"key":"1189_CR12","first-page":"105","volume":"4","author":"M Dom\u00e9nech","year":"2010","unstructured":"Dom\u00e9nech M, Coca A. Role of triple fixed combination valsartan, amlodipine and hydrochlorothiazide in controlling blood pressure. Patient preference adherence. 2010;4:105\u201313.","journal-title":"Patient preference adherence"},{"key":"1189_CR13","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1097\/HJH.0000000000002089","volume":"37","author":"A Salam","year":"2019","unstructured":"Salam A, Atkins ER, Hsu B, Webster R, Patel A, Rodgers A. Efficacy and safety of triple versus dual combination blood pressure-lowering drug therapy: a systematic review and meta-analysis of randomized controlled trials. J Hypertens. 2019;37:1567\u201373.","journal-title":"J Hypertens"},{"key":"1189_CR14","doi-asserted-by":"crossref","unstructured":"Dhurjati R, Pant R, Satheesh G, Mittal A, Rodgers A, Salam A. Efficacy and safety of triple versus dual combinations of antihypertensive drugs: an updated systematic review and meta-analysis of double-blind randomized clinical trials. medRxiv [Preprint]. 2026; 26356990.","DOI":"10.64898\/2026.07.03.26356990"},{"key":"1189_CR15","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1016\/S0140-6736(24)01744-6","volume":"404","author":"A Rodgers","year":"2024","unstructured":"Rodgers A, Salam A, Schutte AE, Cushman WC, de Silva HA, Di Tanna GL, et al. Efficacy and safety of a novel low-dose triple single-pill combination of telmisartan, amlodipine and indapamide, compared with dual combinations for treatment of hypertension: a randomised, double-blind, active-controlled, international clinical trial. Lancet. 2024;404:1536\u201346.","journal-title":"Lancet"},{"key":"1189_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2025.101883","volume":"4","author":"N Wang","year":"2025","unstructured":"Wang N, Rueter P, Salam A, Huffman MD, Atkins E, Ojji D, et al. Low-dose combinations with 3 or 4 blood pressure-lowering medications for the treatment of hypertension. JACC Adv. 2025;4:101883.","journal-title":"JACC Adv"},{"key":"1189_CR17","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/S0140-6736(21)01922-X","volume":"398","author":"CK Chow","year":"2021","unstructured":"Chow CK, Atkins ER, Hillis GS, Nelson MR, Reid CM, Schlaich MP, et al. Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial. Lancet. 2021;398:1043\u201352.","journal-title":"Lancet"},{"key":"1189_CR18","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1038\/s41440-024-01658-y","volume":"47","author":"MD Huffman","year":"2024","unstructured":"Huffman MD, Baldridge AS, Lazar D, Abbas H, Mejia J, Flowers FM, et al. Efficacy and safety of a four-drug, quarter-dose treatment for hypertension: the QUARTET USA randomized trial. Hypertens Res. 2024;47:1668\u201377.","journal-title":"Hypertens Res"},{"key":"1189_CR19","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1001\/jama.2018.10359","volume":"320","author":"R Webster","year":"2018","unstructured":"Webster R, Salam A, de Silva HA, Selak V, Stepien S, Rajapakse S, et al. Fixed low-dose triple combination antihypertensive medication vs usual care for blood pressure control in patients with mild to moderate hypertension in sri lanka: a randomized clinical trial. JAMA. 2018;320:566\u201379.","journal-title":"JAMA"},{"key":"1189_CR20","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1001\/jama.2024.18080","volume":"332","author":"DB Ojji","year":"2024","unstructured":"Ojji DB, Salam A, Sani MU, Ogah OS, Schutte AE, Huffman MD, et al. Low-dose triple-pill vs standard-care protocols for hypertension treatment in nigeria: a randomized clinical trial. JAMA. 2024;332:1070\u20139.","journal-title":"JAMA"},{"key":"1189_CR21","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1056\/NEJMoa2515043","volume":"394","author":"CS Anderson","year":"2026","unstructured":"Trident Research Group, Anderson CS, Chow CK, de Silva HA, Senanayake B, Wahab K, et al. Three low-dose antihypertensive agents in a single pill after intracerebral hemorrhage. N Engl J Med. 2026;394:1571\u201382.","journal-title":"N Engl J Med"},{"key":"1189_CR22","doi-asserted-by":"publisher","first-page":"102","DOI":"10.5334\/gh.1481","volume":"20","author":"A Salam","year":"2025","unstructured":"Salam A, de Silva HA, Ojji D, de Silva AP, Galappatthy G, Lakshman P, et al. Long-term efficacy and safety of a novel low-dose triple single-pill combination for the treatment of hypertension. Glob Heart. 2025;20:102.","journal-title":"Glob Heart"},{"key":"1189_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2025.102175","volume":"4","author":"V Madrini Jr","year":"2025","unstructured":"Madrini V Jr, Tavares CAM, Albuquerque MTA, Silvestre OM, Felicio JS, et al. Efficacy and safety of a novel triple single-pill for uncontrolled hypertension. OPTION TREAT Trial JACC Adv. 2025;4:102175.","journal-title":"OPTION TREAT Trial JACC Adv"},{"key":"1189_CR24","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1097\/HJH.0000000000003636","volume":"42","author":"G Satheesh","year":"2024","unstructured":"Satheesh G, Dhurjati R, Huffman MD, Rosende A, Rodgers A, Prabhakaran D, et al. Standardized treatment protocols for hypertension: global availability, characteristics, and alignment with the hypertension guideline recommendations. J Hypertension. 2024;42:902\u20138.","journal-title":"J Hypertension"},{"key":"1189_CR25","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","volume":"75","author":"T Unger","year":"2020","unstructured":"Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 international society of hypertension global hypertension practice guidelines. Hypertension. 2020;75:1334\u201357.","journal-title":"Hypertension"},{"key":"1189_CR26","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.030696","volume":"12","author":"RD Brook","year":"2023","unstructured":"Brook RD, Brook AJ, Jamerson K, Levy PD, Kaciroti N. Worse blood pressure levels and control during nonsummer months in rigorously treated patients with hypertension: the ACCOMPLISH trial. J Am Heart Assoc. 2023;12:e030696.","journal-title":"J Am Heart Assoc"},{"key":"1189_CR27","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","volume":"373","author":"JT Wright Jr","year":"2015","unstructured":"Sprint Research Group, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103\u201316.","journal-title":"N Engl J Med"},{"key":"1189_CR28","doi-asserted-by":"publisher","first-page":"n189","DOI":"10.1136\/bmj.n189","volume":"372","author":"A Albasri","year":"2021","unstructured":"Albasri A, Hattle M, Koshiaris C, Dunnigan A, Paxton B, Fox SE, et al. Association between antihypertensive treatment and adverse events: systematic review and meta-analysis. BMJ. 2021;372:n189.","journal-title":"BMJ"},{"key":"1189_CR29","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/s41371-022-00766-x","volume":"37","author":"SK Sahoo","year":"2023","unstructured":"Sahoo SK, Pathni AK, Krishna A, Sharma B, Cazabon D, Moran AE, et al. Financial implications of protocol-based hypertension treatment: an insight into medication costs in public and private health sectors in India. J Hum Hypertens. 2023;37:828\u201334.","journal-title":"J Hum Hypertens"},{"key":"1189_CR30","unstructured":"Resolve to Save Lives. Under Pressure: Strategies to Improve Access to Medicines to Treat High Blood Pressure in Low- and Middle-Income Countries New York: Resolve to Save Lives: 2022."},{"key":"1189_CR31","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1111\/jch.14143","volume":"23","author":"S Negi","year":"2021","unstructured":"Negi S, Neupane D, Sahoo SK, Mahajan T, Swaroop K, Moran AE, et al. Prices of combination medicines and single-molecule antihypertensive medicines in India\u2019s private health care sector. J Clin Hypertens. 2021;23:738\u201343.","journal-title":"J Clin Hypertens"},{"key":"1189_CR32","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1097\/HJH.0000000000004050","volume":"43","author":"M Pikkemaat","year":"2025","unstructured":"Pikkemaat M, Atkins ER, Rodgers A, Schutte AE. Treating hypertension with single pill combinations: a simple strategy to save costs for the patients and payers. J Hypertens. 2025;43:1478\u201384.","journal-title":"J Hypertens"},{"key":"1189_CR33","doi-asserted-by":"publisher","first-page":"e0161285","DOI":"10.1371\/journal.pone.0161285","volume":"11","author":"SG Mallat","year":"2016","unstructured":"Mallat SG, Tanios BY, Itani HS, Lotfi T, Akl EA. Free versus fixed combination antihypertensive therapy for essential arterial hypertension: a systematic review and meta-analysis. PLoS One. 2016;11:e0161285.","journal-title":"PLoS One"},{"key":"1189_CR34","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1093\/ehjcvp\/pvae059","volume":"10","author":"B Weisser","year":"2025","unstructured":"Weisser B, Wassmann S, Predel HG, Schmieder RE, Gillessen A, Wilke T, et al. Effect of a single pill concept on clinical and pharmacoeconomic outcomes in cardiovascular diseases. Eur Heart J Cardiovasc Pharmacother. 2025;10:686\u201393.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"1189_CR35","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1111\/j.1751-7176.2011.00550.x","volume":"13","author":"B Sherrill","year":"2011","unstructured":"Sherrill B, Halpern M, Khan S, Zhang J, Panjabi S. Single-pill vs free-equivalent combination therapies for hypertension: a meta-analysis of health care costs and adherence. J Clin Hypertens. 2011;13:898\u2013909.","journal-title":"J Clin Hypertens"},{"key":"1189_CR36","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/ajh.2008.31","volume":"21","author":"A Rabbani","year":"2008","unstructured":"Rabbani A, Alexander GC. Out-of-pocket and total costs of fixed-dose combination antihypertensives and their components. Am J Hypertens. 2008;21:509\u201313.","journal-title":"Am J Hypertens"},{"key":"1189_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-13-124","volume":"13","author":"M Akazawa","year":"2013","unstructured":"Akazawa M, Fukuoka K. Economic impact of switching to fixed-dose combination therapy for Japanese hypertensive patients: a retrospective cost analysis. BMC Health Serv Res. 2013;13:124.","journal-title":"BMC Health Serv Res"},{"key":"1189_CR38","first-page":"e151","volume":"16","author":"V Stankus","year":"2009","unstructured":"Stankus V, Hemmelgarn B, Campbell NR, Chen G, McAlister FA, Tsuyuki RT. Reducing costs and improving hypertension management. Can J Clin Pharmacol. 2009;16:e151\u20135.","journal-title":"Can J Clin Pharmacol"},{"key":"1189_CR39","doi-asserted-by":"publisher","first-page":"3569","DOI":"10.1161\/CIRCULATIONAHA.105.535922","volume":"112","author":"TA Gaziano","year":"2005","unstructured":"Gaziano TA, Steyn K, Cohen DJ, Weinstein MC, Opie LH. Cost-effectiveness analysis of hypertension guidelines in South Africa: absolute risk versus blood pressure level. Circulation. 2005;112:3569\u201376.","journal-title":"Circulation"},{"key":"1189_CR40","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1161\/CIRCULATIONAHA.115.019985","volume":"133","author":"S Basu","year":"2016","unstructured":"Basu S, Yudkin JS, Sussman JB, Millett C, Hayward RA. Alternative strategies to achieve cardiovascular mortality goals in china and india: a microsimulation of target- versus risk-based blood pressure treatment. Circulation. 2016;133:840\u20138.","journal-title":"Circulation"},{"key":"1189_CR41","doi-asserted-by":"publisher","first-page":"e1001860","DOI":"10.1371\/journal.pmed.1001860","volume":"12","author":"D Gu","year":"2015","unstructured":"Gu D, He J, Coxson PG, Rasmussen PW, Huang C, Thanataveerat A, et al. The cost-effectiveness of low-cost essential antihypertensive medicines for hypertension control in china: a modelling study. PLoS Med. 2015;12:e1001860.","journal-title":"PLoS Med"},{"key":"1189_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta7310","volume":"7","author":"M Law","year":"2003","unstructured":"Law M, Wald N, Morris J. Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy. Health Technol Assess. 2003;7:1\u201394.","journal-title":"Health Technol Assess"},{"key":"1189_CR43","doi-asserted-by":"publisher","first-page":"e1359","DOI":"10.1016\/S2214-109X(19)30343-2","volume":"7","author":"T Lung","year":"2019","unstructured":"Lung T, Jan S, de Silva HA, Guggilla R, Maulik PK, Naik N, et al. Fixed-combination, low-dose, triple-pill antihypertensive medication versus usual care in patients with mild-to-moderate hypertension in Sri Lanka: a within-trial and modelled economic evaluation of the TRIUMPH trial. Lancet Glob Health. 2019;7:e1359\u2013e66.","journal-title":"Lancet Glob Health"},{"key":"1189_CR44","doi-asserted-by":"publisher","first-page":"45","DOI":"10.5334\/gh.1428","volume":"20","author":"A Rosende","year":"2025","unstructured":"Rosende A, Romero C, DiPette DJ, Brettler J, Van der Stuyft P, Satheesh G, et al. Candidate interventions for integrating hypertension and cardiovascular-kidney-metabolic care in primary health settings: HEARTS 2.0 phase 1. Glob Heart. 2025;20:45.","journal-title":"Glob Heart"},{"key":"1189_CR45","unstructured":"Pan American Health Organization. HEARTS 20 clinical pathway: standard. Washington (DC); PAHO: 2026 [cited 2026 May 19]. https:\/\/www.paho.org\/sites\/default\/files\/2026\/05\/hearts-20-clinical-pathwayeng-1.pdf."},{"key":"1189_CR46","doi-asserted-by":"publisher","first-page":"e018550","DOI":"10.1136\/bmjgh-2024-018550","volume":"10","author":"M Hellamand","year":"2025","unstructured":"Hellamand M, Moleman TE, Post AP, Mantel-Teeuwisse AK, Suleman F, van den Ham HA. Time to inclusion of selected medicines for priority diseases in national essential medicines lists compared with the WHO Model List. BMJ Glob Health. 2025;10:e018550.","journal-title":"BMJ Glob Health"},{"key":"1189_CR47","doi-asserted-by":"publisher","first-page":"73","DOI":"10.5334\/gh.1457","volume":"20","author":"EG Ferro","year":"2025","unstructured":"Ferro EG, Satheesh G, Castellano J, Damasceno A, Erojikwe O, Huffman M, et al. WHF roadmap on single pill combination therapies. Glob Heart. 2025;20:73.","journal-title":"Glob Heart"},{"key":"1189_CR48","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jacc.2025.06.006","volume":"86","author":"A Rodgers","year":"2025","unstructured":"Rodgers A, Satheesh G, Murphy A. The potential of single pill combinations. J Am Coll Cardiol. 2025;86:162\u20134.","journal-title":"J Am Coll Cardiol"},{"key":"1189_CR49","doi-asserted-by":"publisher","first-page":"6","DOI":"10.5334\/gh.1087","volume":"17","author":"E Bruyn","year":"2022","unstructured":"Bruyn E, Nguyen L, Schutte AE, Murphy A, Perel P, Webster R. Implementing single-pill combination therapy for hypertension: a scoping review of key health system requirements in 30 low- and middle-income countries. Glob Heart. 2022;17:6.","journal-title":"Glob Heart"},{"key":"1189_CR50","unstructured":"Pan American Health Organization. Strategic Fund: Access to quality medicines and health supplies in the Americas. Washington, DC: PAHO; 2018."},{"key":"1189_CR51","doi-asserted-by":"publisher","first-page":"283","DOI":"10.2471\/BLT.15.154385","volume":"93","author":"N Magrini","year":"2015","unstructured":"Magrini N, Robertson J, Forte G, Cappello B, Moja LP, De Joncheere K, et al. Tough decisions on essential medicines in 2015. Bull World Health Organ. 2015;93:283\u20134.","journal-title":"Bull World Health Organ"}],"container-title":["Journal of Human Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41371-026-01189-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41371-026-01189-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41371-026-01189-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T10:04:06Z","timestamp":1786615446000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41371-026-01189-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":51,"alternative-id":["1189"],"URL":"https:\/\/doi.org\/10.1038\/s41371-026-01189-8","relation":{},"ISSN":["1476-5527"],"issn-type":[{"value":"1476-5527","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]},"assertion":[{"value":"19 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MDH has received travel support from the World Heart Federation and consulting fees from PwC Switzerland. MDH has pending patents for heart failure polypills. AES has received speaker honoraria from Servier, AstraZeneca, Medtronic, Omron, Novo Nordisk and Aktiia and serves on scientific advisory boards for Medtronic, Roche\/Alnylam, AstraZeneca, Servier, SiSU Health, Biozen and Sky Labs. MDH, AES, and AR has an appointment at The George Institute for Global Health, which has a patent, license, and has received investment funding with intent to commercialize fixed-dose combination therapy through its social enterprise business, George Medicines.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}